Mithramycin for Lung, Esophagus, and Other Chest Cancers : Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Background: - Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment. Research suggests that it may be useful against some cancers of the chest, such as lung and esophageal cancer or mesothelioma. Researchers want to see if mithramycin can be used to treat these types of cancer. Objectives: - To see if mithramycin is safe and effective against different chest cancers. Eligibility: - Individuals at least 18 years of age who have lung, esophagus, pleura, or mediastinum cancers. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and tumor tissue samples will be used to monitor the cancer before treatment. - Participants will receive mithramycin every day for 7 days, followed by 7 days without treatment. Each 14-day round of treatment is called a cycle. - Treatment will be monitored with frequent blood tests and imaging studies. - Participants will continue to take the drug for as long as the side effects are not severe and the tumor responds to treatment..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
ClinicalTrials.gov - (2019) vom: 30. Dez. Zur Gesamtaufnahme - year:2019 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: June 20, 2012, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 |
|---|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG001272977 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG001272977 | ||
| 003 | DE-627 | ||
| 005 | 20230425194822.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG001272977 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT01624090 | ||
| 035 | |a (UBBS_Klinische_Studien)120151 | ||
| 035 | |a (UBBS_Klinische_Studien)12-C-0151 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Mithramycin for Lung, Esophagus, and Other Chest Cancers |b Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: June 20, 2012, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 | ||
| 520 | |a Background: - Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment. Research suggests that it may be useful against some cancers of the chest, such as lung and esophageal cancer or mesothelioma. Researchers want to see if mithramycin can be used to treat these types of cancer. Objectives: - To see if mithramycin is safe and effective against different chest cancers. Eligibility: - Individuals at least 18 years of age who have lung, esophagus, pleura, or mediastinum cancers. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and tumor tissue samples will be used to monitor the cancer before treatment. - Participants will receive mithramycin every day for 7 days, followed by 7 days without treatment. Each 14-day round of treatment is called a cycle. - Treatment will be monitored with frequent blood tests and imaging studies. - Participants will continue to take the drug for as long as the side effects are not severe and the tumor responds to treatment. | ||
| 650 | 2 | |a Mesothelioma | |
| 650 | 2 | |a Gastrointestinal Neoplasms | |
| 650 | 2 | |a Digestive System Neoplasms | |
| 650 | 4 | |a Medical Condition: Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Neoplasms, Breast Cancer | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Terminated | |
| 650 | 4 | |a Phase: Phase 2 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2019) vom: 30. Dez. |
| 773 | 1 | 8 | |g year:2019 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT01624090 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2019 |b 30 |c 12 | ||